Literature DB >> 6190057

The efficacy of a serum screening service for neural-tube defects: the South Wales experience.

C J Roberts, B M Hibbard, G H Elder, K T Evans, K M Laurence, A Roberts, J S Woodhead, I B Robertson, M Hoole.   

Abstract

Serum-alpha-fetoprotein (AFP) levels were measured in more than 15 000 pregnant women in an investigation designed to examine the operational issues entailed in a large-scale population screening programme for antenatal detection of neural-tube defects. The proportion of open neural-tube defects (ONTD) terminated as a result of serum screening was 56.1% (66.6% for anencephaly and 40.7% for open spina bifida). The principle causes of poor efficacy were: failure of pregnant women to undergo screening (18.2% of ONTD were not screened); failure of the screening test to detect ONTD (20.4% of those screened were below the 90th centile); decisions against termination of detected ONTD (14% of ONTD detected by serum AFP were not terminated). Given present practices and knowledge it is doubtful whether overall efficacy levels above 65% for open spina bifida can be achieved under normal service conditions. The establishment of a regional or national screening programme on grounds of clinical efficacy alone may be premature. The decision would seem to hinge principally around a careful consideration of the economic issues.

Entities:  

Keywords:  Genetics and Reproduction

Mesh:

Substances:

Year:  1983        PMID: 6190057     DOI: 10.1016/s0140-6736(83)92424-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  9 in total

1.  Ethics, justification and the prevention of spina bifida.

Authors:  Wendy Jane Gagen; Jeffrey P Bishop
Journal:  J Med Ethics       Date:  2007-09       Impact factor: 2.903

2.  Can we afford screening for neural tube defects.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-02

3.  Maternal serum alpha-fetoprotein screening for neural tube defects. Report of a combined study in Germany and short overview on screening in populations with low birth prevalence of neural tube defects.

Authors:  W Fuhrmann; H K Weitzel
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

4.  A study of the value of measuring maternal serum alpha-fetoprotein for the antenatal diagnosis of neural tube defects.

Authors:  J Tidy
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

5.  Which prescriptive screening programmes are worth while?

Authors:  J M Chamberlain
Journal:  J Epidemiol Community Health       Date:  1984-12       Impact factor: 3.710

6.  Should women at high risk of neural tube defect have an amniocentesis?

Authors:  K M Laurence; G Elder; K T Evans; B M Hibbard; M Hoole; C J Roberts
Journal:  J Med Genet       Date:  1985-12       Impact factor: 6.318

7.  Periodic health examination, 1994 update: 3. Primary and secondary prevention of neural tube defects. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1994-07-15       Impact factor: 8.262

8.  Can we afford screening for neural tube defects? The South Wales experience.

Authors:  B M Hibbard; C J Roberts; G H Elder; K T Evans; K M Laurence
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-26

9.  Neural tube defects--prenatal diagnosis and management.

Authors:  R A Hamilton; J C Dornan
Journal:  Ulster Med J       Date:  1992-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.